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bjectives This study intended to compare outcomes between transradial (TR) and transfemoral
TF) percutaneous revascularization in high-risk coronary anatomy.
ackground The feasibility, efﬁcacy and safety between TR and TF methods of percutaneous
oronary revascularization for unprotected left main coronary artery (UPLM]) disease have not
een compared.
ethods Among 821 consecutive patients with UPLM disease treated with percutaneous revascu-
arization by either TR (n  353) or TF (n  468) vascular access, procedural outcomes, resource use,
n-hospital bleeding, and late clinical events were compared according to vascular access method.
esults Clinical and angiographic characteristics were similar between groups, except that TR pa-
ients less commonly presented with unstable angina and had less UPLM bifurcation disease requir-
ng treatment with 2 stents. No signiﬁcant differences were observed between TR and TF methods
or procedural success (97% TF vs. 96% TR, p  0.57) or total procedural time. However, duration of
ospital stay and in-hospital occurrence of Thrombosis In Myocardial Infarction (TIMI) major or mi-
or bleeding (0.6% vs. 2.8%, p  0.02) were signiﬁcantly lower with TR access. Using propensity
core modeling (254 matched pairs), over a mean follow-up period of 17 months, rates of cardiovas-
ular death (1.2% vs. 2.0%, p  0.48), nonfatal myocardial infarction (4.7% vs. 2.4%, p  0.16), stent
hrombosis (0.8% vs. 2.8%, p  0.10) and any target vessel revascularization (6.0% vs. 6.7%, p 
.72) did not statistically differ among TR and TF groups, respectively.
onclusions In contrast to TF vascular access, TR percutaneous coronary revascularization for UPLM
isease is feasible and associated with similar procedural success, abbreviated hospitalization, re-
uced bleeding, and comparable late-term clinical safety and efﬁcacy. (J Am Coll Cardiol Intv 2010;
:1035–42) © 2010 by the American College of Cardiology Foundation
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1036ompared with transfemoral (TF) vascular access, transra-
ial (TR) percutaneous coronary intervention (PCI) is
ssociated with clinically significant reductions in
rocedural-related bleeding complications and improved
atient satisfaction (1–9), yet its adoption has remained a
imited procedure in many geographies. In part related to
perator inexperience (10–12), increasing performance of
R PCI is also challenged by an incomplete evidence basis,
urthering perceptions that the practicality of TR PCI may
e restricted to less complex coronary anatomy and lower
isk clinical settings.
Unprotected left main coronary artery (UPLM) disease
epresents a particularly challenging lesion subset for per-
utaneous coronary revascularization. Despite an evolving
vidence basis and guideline recommendations supporting
he relative safety and efficacy of UPLM PCI compared
ith surgical revascularization (13,14), technical complexi-
ties related to stent technique
and bifurcation disease represent
unresolved procedural-related
dilemmas for interventionalists.
Considering the practical limita-
tions associated with TR PCI in
high-risk lesion anatomy (e.g.,
guiding catheter support, equip-
ment size restrictions), UPLM
disease challenges the feasibility
of a transradial procedural strat-
egy compared with a more stan-
dard femoral approach. Our
purpose, therefore, was to com-
pare procedural results, resource
use, and clinical outcomes be-
tween TR and TF methods of
percutaneous coronary revascu-
larization with drug-eluting
stents (DES) for UPLM disease.
ethods
tudy population. Between April 2004 and April 2009,
onsecutive patients undergoing UPLM PCI with DES at
he Fu Wai Hospital in Beijing, China, were evaluated for
n-hospital and late-term outcomes. Unprotected left main
oronary disease was defined as documented myocardial
schemia with 50% UPLM stenosis and no patent bypass
raft to the left anterior descending or left circumflex
rteries. In general, the decision for UPLM PCI was based
n consultation with both patients and surgeons in the
etting of isolated UPLM disease or in situations of mul-
ilesion treatment amenable to complete revascularization
ith stent placement. For those patients with UPLM
tenosis and more complex multivessel disease, PCI was
bbreviations
nd Acronyms
ES  drug-eluting stent(s)
VUS  intravascular
ltrasound
ACE  major adverse
ardiac events
I  myocardial infarction
CI  percutaneous
oronary intervention
F  transfemoral
IMI  Thrombolysis In
yocardial Infarction
R  transradial
VR  target vessel
evascularization
PLM  unprotected left
ain coronary arterylected in instances of patient refusal for surgery or comor- didity that posed excessive surgical risk. Patients were
xcluded from the present analysis in instances of contrain-
ication for antiplatelet therapy, acute myocardial infarction
MI) within 7 days, or bailout stenting of the left main
rtery due to PCI-related complications (e.g., dissection,
hrombus) of non-left main target lesions.
rocedural details. Vascular access method and stent tech-
ique were performed according to the operator’s discretion.
stial or shaft lesions without distal bifurcation involve-
ent were typically treated with a single stent. Stent
trategies to treat distal bifurcation lesions included: cross-
ver stenting with side branch balloon angioplasty, provi-
ional or dedicated T stenting, simultaneous kissing or V
tenting (TF approach only), Culotte or crush technique
including “step crush” technique involving sequential bal-
oon crushing of side branch stent followed by main vessel
tenting). Final kissing balloon post-dilation was performed
n cases with suboptimal results after crossover stenting at
he side branch ostium and, in most cases, with 2-stent
mplantation. Intravascular ultrasound (IVUS)– guided
tenting was encouraged to achieve optimal stent expansion
nd lesion coverage. Stent type and brand were selected per
he treating physician’s discretion among those commer-
ially available at the time of the study, namely, the
irolimus-eluting Cypher stent (Cordis, Europa N.V., LJ
oden, the Netherlands), paclitaxel-eluting Taxus stent
Boston Scientific, Galway, Ireland), sirolimus-eluting Fire-
ird stent (MicroPort, Shanghai, China), and sirolimus-
luting Excel stent (JW Medical Co., Ltd., Shandong,
hina).
Before the procedure, all patients received aspirin, 300
g daily, and a 300-mg loading dose of clopidogrel was
iven at least 1 day before the procedure. During the
rocedure, unfractionated heparin (100 U/kg) was admin-
stered to all patients, and use of glycoprotein IIb/IIIa
nhibitors was per the operator’s judgment. After the pro-
edure, aspirin was prescribed at a dose of 300 mg daily for
months, followed by 100 mg daily indefinitely; clopidogrel
5 mg daily was prescribed for at least 1 year.
atient follow-up. All patients were evaluated by clinic visit
r by phone at 1, 3, 6, and 12 months and annually
hereafter. Per local standards, all patients were advised to
eturn for coronary angiography 6 months following the
ndex procedure, or earlier if clinically indicated by symp-
oms or documentation of myocardial ischemia. Two inde-
endent, experienced staff members analyzed all baseline
nd follow-up angiographic results. Quantitative coronary
ngiography analysis was performed with QUANTCOR
CA (CAAS II) Version 5.0 (Pie Medical Imaging,
aastricht, the Netherlands). Binary restenosis was defined
s50% diameter stenosis at follow-up and was classified as
n-stent or in-segment if located within 5 mm proximal or
istal to the stent margin.
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1037tudy end points. Angiographic success was defined as a
esidual stenosis of 30% by visual estimation in the
resence of Thrombosis In Myocardial Infarction (TIMI)
ow grade 3. Procedural success was defined as achievement
f TIMI flow grade 3 with a final residual stenosis of 30%
ithout in-hospital death, MI, or emergency coronary
rtery bypass surgery. Myocardial infarction was diagnosed
y electrocardiographic changes and/or a rise and fall of
reatine kinase-myocardial band fraction in the presence of
schemic symptoms. New development of pathological Q
aves in 2 contiguous leads was defined as Q-wave MI; and
n the absence of pathological Q waves, an elevation in
reatine kinase-myocardial band level 2 times the upper
imit of normal was defined as non–Q-wave MI. Target
essel revascularization (TVR) was determined as any re-
eated PCI or bypass grafting surgery to treat a luminal
enarrowing in-stent or within 5-mm borders adjacent to
he stent, including the ostia of the left coronary arteries.
eath that could not be attributed to a noncardiac etiology
as considered cardiovascular death. Major adverse cardiac
vents (MACE) was defined as the occurrence of cardio-
ascular death, nonfatal MI, and TVR in hospital and
uring follow-up. Stent thrombosis was adjudicated accord-
ng to Academic Research Consortium definitions as defi-
ite, probable, and possible classifications (15). Bleeding
vents were evaluated during hospitalization and character-
zed according to TIMI (major, minor) and GUSTO
Global Use of Strategies to Open Coronary Arteries)
moderate, severe) study criteria in addition to any reported
leeding (16,17).
tatistical analysis. Patient demographics, including base-
ine clinical, angiographic, and procedural characteristics
rom TR and TF groups were described using means for
ontinuous variables and frequencies for categorical vari-
bles. Proportions were compared between groups using
hi-square analysis and Fisher exact test where appropriate.
roup means were compared using Student t test. Cumu-
ative event rates were estimated by the Kaplan-Meier
ethod and tested by the log-rank statistic. Differences in
he incidence rates of individual clinical outcomes and
omposite outcomes between patients undergoing the 2
rocedures were investigated by developing multivariable
ox proportional hazards models after confirming that the
roportional hazards assumption was met. Adjusted relative
isks were estimated with the potential confounders entered
s covariates.
Because the choice of procedure was not randomized, a
:1 matched propensity score analysis was performed to
inimize bias. The transradial patients were ordered and
equentially matched to the nearest unmatched transfemoral
atients according to the estimated propensity score. Pro-
ensity scores were calculated using the following baseline
ariables as predictors: sex, age, prior MI, prior PCI,
revious coronary artery bypass surgery, diabetes mellitus,nstable angina, lesion complexity (class B2/C), left main
ifurcation lesion, pre-dilation angioplasty, sirolimus-
luting stent treatment, stent diameter, stent length, use of
ntravascular ultrasound, post-dilation angioplasty, and
reatment with intra-aortic balloon counterpulsation. If the
ifference of the estimated propensity score between tran-
radial and transfemoral group is 0.001, then these 2
atents were eligible for matching. Paired t tests for con-
inuous variables or McNemar test for categorical variables
ere used for comparison within the matched pairs.
aplan-Meier curves also were constructed for study out-
omes in the matched cohort. Matched Cox regression
nalysis was employed to determine the effect of 2 proce-
ures on clinical outcomes. Matched Cox regression anal-
sis is a stratified analysis that uses each pair of matched
atients as a separate stratum to compare survival within
ach pair, which is then used to estimate the overall hazard
atio. All analyses were conducted using SAS software,
ersion 9.13 (SAS Institute, Cary, North Carolina), and a
-sided p value of 0.05 or less was considered to indicate
tatistical significance.
esults
mong 19,978 patients treated with PCI between April
004 to April 2009, 821 consecutive patients (4.1%) under-
Table 1. Baseline Clinical and Angiographic Characteristics
Transradial
(n  353)
Transfemoral
(n  468) p Value
Age, yrs 59  11 61  11 0.02
Men 275 (78) 360 (77) 0.72
Prior MI 88 (25) 131 (28) 0.31
Prior PCI 81 (23) 117 (25) 0.50
Diabetes mellitus* 84 (24) 112 (24) 1.00
Hypertension* 187 (53) 253 (54) 0.85
Hyperlipidemia* 123 (35) 145 (31) 0.21
Previous stroke 7 (2) 9 (2) 0.95
Current smoker 102 (29) 140 (30) 0.68
Unstable angina 131 (37) 230 (49) 0.01
Ejection fraction 58  10 59  11 0.79
Lesion location 0.56
Isolated UPLM 78 (22) 89 (19)
UPLM with 1 vessel 71 (20) 108 (23)
LM with 2 vessel 120 (34) 168 (36)
LM with 3 vessel 84 (24) 103 (22)
UPLM lesion distribution 0.01
Ostium 71 (20) 56 (12)
Shaft 85 (24) 98 (21)
Bifurcation 197 (56) 314 (67)
Data represented as n (%) or mean SD. *Defined as requiring medical therapy.
LM left main; MImyocardial infarction; PCI percutaneous coronary intervention;UPLM unprotected left main.
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1038ent UPLM PCI with DES. The method of vascular access
ncluded 353 TR (43.0%) and 468 TF procedures.
linical and procedural characteristics. Baseline clinical and
esion characteristics are represented in Table 1. Overall,
atients in the TF group were older (61  11 vs. 59  11
ears, p  0.02) and more frequently presented with
nstable angina (49% vs. 37%, p  0.01). Approximately
ne-fourth of patients in each cohort were diabetic. Al-
hough there were no differences regarding multivessel
oronary disease, left main bifurcation disease was signifi-
antly more common in the TF group than with TR
atients. Most patients received treatment with sirolimus-
luting stents (77% overall; 75% TR, 79% TF, p  0.11 for
omparison).
Overall stent length and number of lesions treated did not
tatistically differ between TR and TF groups (Table 2).
pecific to the left main target lesion, stent length was also
imilar, yet a TF approach was more commonly associated
Table 2. Procedural Characteristics and Outcomes
Transradial
(n  353)
Transfemoral
(n  468) p Value
UPLM treatment characteristics
LM PCI technique (%) 0.01
Single stent 256 (81) 290 (62)
Bifurcation stenting 67 (19) 178 (38)
DES type 0.11
Sirolimus-eluting 280 (79) 349 (75)
Paclitaxel-eluting 73 (21) 119 (25)
Guiding catheter size, F 6.1 0.4 6.9 0.8 0.01
Treated lesions/patient 1.7 0.3 1.7 0.3 0.86
Diameter stenosis before (%) 80.6 15.6 82.1 13.0 0.21
Pre-dilation (%) 275 (78) 393 (84) 0.08
UPLM stent diameter, mm 3.51 0.47 3.59 0.49 0.51
UPLM stent length, mm 27.3 16.6 27.8 15.8 0.67
Total stent length, mm 37.3 15.3 37.6 14.9 0.71
Maximal UPLM stent deployment
pressure, atm
15.5 3.6 15.3 3.1 0.52
Overlapping stents (%) 88 (25) 145 (31) 0.06
Post-dilation (%) 251 (71) 357 (76) 0.12
Final kissing balloon (%) 176 (50) 346 (74) 0.01
Diameter stenosis after (%) 14.2 5.2 15.6 6.2 0.10
IVUS (%) 166 (47) 351 (75) 0.01
Hemodynamic support with IABP (%) 18 (5) 51 (11) 0.01
Glycoprotein IIb/IIIa antagonist (%) 25 (7) 42 (9) 0.30
Procedural outcomes
UPLM angiographic success (%) 350 (99) 463 (99) 1.00
Procedural success (%) 342 (97) 450 (96) 0.57
Procedure time, min 61.6 10.9 62.7 10.2 0.13
Fluoroscopy time, min 25.0 8.7 26.1 8.5 0.08
Contrast volume, ml 311 51 320 65 0.02
Data represented as n (%) or mean SD.
DES  drug-eluting stent(s); IABP  intra-aortic balloon pump; IVUS  intravascular ultra-
sound; other abbreviations as in Table 1.ith performance of bifurcation stenting (38% vs. 19%, p .01) and larger guiding catheter caliber. For TR patients
eceiving 2 stents for UPLM PCI (19%, 67 patients),
ifurcation stent technique included stepped crush (72%), T
tenting (22%) and Culotte (6%). Among TF bifurcation
ases treated with a 2-stent technique (178 patients, 38%),
trategies were crush (60%), T stenting (17%), kissing or V
tenting (16%) and Culotte (7%). Use of intravascular
ltrasound and hemodynamic support were also signifi-
antly more common with TF access. Conversely, total
uoroscopy time (min: 25.0 8.7 vs. 26.1 8.5, p 0.08)
nd contrast volume (ml: 311  51 vs. 320  65, p  0.02)
ere lower among TR PCI patients. Despite such differ-
nces, left main–specific angiographic success rates were
ery high in each cohort, and overall procedural success rates
ere similar between treatment strategies.
linical and angiographic outcomes. During hospitaliza-
ion, no differences were observed in the rates of cardiovas-
ular death, MI, TVR, or composite end points (Table 3).
owever, hospital stay duration was significantly shorter
mong TR PCI patients (days: 8.5  5.9 vs. 9.9  5.9, p 
.001), a difference driven by decreased hospitalization time
ost-revascularization (days: 4.5  4.0 vs. 5.1  3.4, p 
.01).
In-hospital bleeding events were significantly lower with
R PCI compared with a TF approach. Specifically, the
ombined occurrence of TIMI major and minor bleeding
as 0.6% and 2.8% in the TR and TF groups, respectively
p  0.02). A vascular closure device was employed in 191
Table 3. In-Hospital and Late Clinical Outcomes
Transradial
(n  353)
Transfemoral
(n  468) p Value
In-hospital outcomes
Cardiovascular death 2 (0.6) 3 (0.6) 1.00
Nonfatal MI 10 (2.8) 7 (1.5) 0.22
Overall TVR (%) 4 (1.1) 9 (1.9) 0.41
Left main speciﬁc TVR (%) 2 (0.6) 5 (1.1) 0.70
MACE 14 (4.0) 15 (3.2) 0.57
Hospital stay duration, days 8.5  5.9 9.9  5.9 0.001
Hospital duration post-revascularization 4.5  4.0 5.1  3.4 0.01
Late clinical outcomes
MACE (%) 36 (10.2) 43 (9.2) 0.63
Cardiac death (%) 5 (1.4) 8 (1.7) 0.74
Nonfatal MI (%) 14 (4.0) 12 (2.6) 0.26
Fatal MI 1 (0.3) 5 (1.1) 0.24
Overall TVR (%) 28 (7.9) 35 (7.5) 0.89
LM-speciﬁc TVR (%) 20 (5.7) 27 (5.8) 0.95
Stent thrombosis (%) 4 (1.1) 12 (2.6) 0.13
Early (%) 1 (0.3) 3 (0.6) 0.64
Late (%) 2 (0.6) 5 (1.1) 0.71
Very late (%) 1 (0.3) 4 (0.9) 0.40
Data represented as n (%) or mean SD.
MACEmajor adverse cardiac events; TVR target vessel revascularization; other abbrevia-tions as in Table 1.
(
b
w
a
U
b
t
a
w
d
s
9
p
s
T
b
t
i
(
m
i
a
C
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 0 , 2 0 1 0 Yang et al.
O C T O B E R 2 0 1 0 : 1 0 3 5 – 4 2 Transradial Left Main Revascularization
103940.8%) of TF patients; among 13 TIMI major and minor
leeding events in the TF cohort, 6 patients were treated
ith vascular closure devices. Moderate and severe bleeding
ccording to GUSTO criteria also tended to be lower with
PLM TR PCI (0.8% vs. 2.8%, p  0.07). Report of any
leeding during hospitalization was significantly lower in
he TR cohort (12.2% vs. 18.2%, p  0.02).
Clinical follow-up was complete for all patients over an
verage 17-month duration, although the follow-up period
as longer for TF patients (587  343 days vs. 442  267
ays, p  0.01). Compared with TF patients, there were no
ignificant differences in rates of MACE (10.2% TF vs.
.2% TR, p  0.63), or the individual component end
Figure 1. Kaplan-Meier Estimates of Major Cardiovascular Events for TR an
(A) Major adverse cardiac events: Kaplan-Meier curves demonstrate no signiﬁc
and transfemoral cohorts. (B) Cardiovascular death: Kaplan-Meier curves demo
transradial and transfemoral cohorts. (C) Myocardial infarction: Kaplan-Meier cu
infarction between transradial and transfemoral cohorts. (D) Target vessel reva
rence of target vessel revascularization between transradial and transfemoral c
no signiﬁcant difference in occurrence of Academic Research Consortium deﬁn
MACE  major adverse cardiac events; MI  myocardial infarction; TF  trans
tected left main coronary artery.oints (Fig. 1, Table 3). Specifically, rates of left main–
pecific TVR (5.8% TF vs. 5.7% TR, p  0.95) and any
VR (7.5% TF vs. 7.9% TR, p  0.89) were similar
etween treatment groups. Definite and probable stent
hrombosis were also similar overall and at differing time
ntervals (early, late, very late) between TR and TF groups
1.1% TR vs. 2.6% TF, p  0.13; Table 3).
Using logistic regression to derive the propensity score
odel, 254 matched patient pairs were compared. Follow-
ng adjustment, only the baseline variable of prior coronary
rtery bypass graft remained statistically significant. The
-statistic for the model was 0.70. In this adjusted model,
here were no significant differences throughout the
UPLM Patients
fference in occurrence of major adverse cardiac events between transradial
e no signiﬁcant difference in occurrence of cardiovascular death between
emonstrate no signiﬁcant difference in occurrence of nonfatal myocardial
ization: Kaplan-Meier curves demonstrate no signiﬁcant difference in occur-
. (E) Deﬁnite or probable stent thrombosis: Kaplan-Meier curves demonstrate
probable stent thrombosis between transradial and transfemoral cohorts.
al; TR  transradial; TVR  target vessel revascularization; UPLM  unpro-d TF
ant di
nstrat
rves d
scular
ohorts
ite or
femor
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1040ollow-up period in adverse event rates; outcomes of car-
iovascular death (1.2% vs. 2.0%, p  0.48), nonfatal MI
4.7% vs. 2.4%, p  0.16), stent thrombosis (0.8% vs. 2.8%,
 0.10), and any target TVR (6.0% vs. 6.7%, p  0.72)
id not statistically differ among TR and TF groups,
espectively. Further, in a multivariate regression analysis,
R method of PCI was not predictive of adverse cardiac
vents (Fig. 2).
At 6 months, angiographic surveillance was performed in
00 (28.3%) TR patients and 264 (56.4%) TF patients (p 
.01 for comparison). For left main lesions, neither in-stent
8.0% TR vs. 12.5% TF, p  0.27) nor in-segment (9.0%
R vs. 14.0% TF, p  0.22) restenosis rates differed
etween treatment methods. For both TR and TF groups,
estenosis most commonly occurred at the ostium of the left
ircumflex artery (5.0% TR vs. 11.0% TF, p  0.11).
iscussion
hrough comparison of procedural and clinical outcomes
ith TF vascular access, these findings extend our under-
tanding of TR PCI to more complex coronary anatomy and
igh-risk clinical settings. The salient findings of this study
re: 1) UPLM PCI, including treatment of distal left main
ifurcation disease, is feasible by the TR method and is
ssociated with high procedural success; 2) bleeding events
re significantly less common with UPLM TR PCI com-
ared with a TF approach; 3) UPLM TR PCI is associated
ith shorter hospital stay duration; and 4) compared with a
F approach and following propensity score adjustment,
Figure 2. Multivariable Matched Propensity Analysis of Major
Adverse Events
Multivariable matched propensity analysis demonstrates no statistically sig-
niﬁcant differences in the incidence rates of individual and composite clini-
cal outcomes between transradial and transfemoral percutaneous coronaryf
intervention cohorts. Abbreviations as in Figure 1.R PCI for UPLM disease is associated with similar early
nd late outcomes of major cardiovascular events.
To our knowledge, this study represents the largest survey
f TR PCI for UPLM disease and the only comparative
eport of vascular access methods for UPLM PCI. Whereas
everal studies have demonstrated the superiority of TR
ascular access over a TF approach for reductions in vascular
ccess and bleeding complications (1–9,18–21), expansion
f TR PCI to more complex and high-risk lesion anatomy
as been restricted by operator inexperience and lack of
upportive evidence. This perception is especially relevant
or UPLM disease, considering the technical challenges of
uiding catheter support, limitations of catheter size and
ftentimes simultaneous need for multiple angioplasty cath-
ters, and consequences of procedural failure.
Limitations regarding guiding catheter size and design
nd equipment constraints notwithstanding, procedural
uccess rates and duration were similar between vascular
ccess methods, demonstrating the feasibility of complex
ercutaneous coronary revascularization by a TR approach.
pecifically, TR PCI with 6-F guiding catheters was asso-
iated with near uniform procedural success despite the
imultaneous requirement of multiple catheters and guide-
ires, and compared with a TF approach, did not increase
uoroscopy time and overall procedural duration. Several
odest-sized randomized and observational trials have
ompared procedural outcomes (including contrast use and
uoroscopy time) between radial and femoral access meth-
ds with variable results (6–8,20–22). In a systematic
verview of 12 randomized trials comparing the radial and
emoral approach for diagnostic and interventional proce-
ures, a significant reduction in vascular access complica-
ions with the radial approach (odds ratio [OR]: 0.20; 95%
onfidence interval [CI]: 0.09 to 0.42) was reported despite
higher likelihood of procedural failure compared with
emoral access (OR: 3.30; 95% CI: 1.63 to 6.71) (8).
lthough this relative reduction in bleeding complications
as similar to that observed in this evaluation, the proce-
ural efficacy observed in the present study is consistent with
ore contemporary trials that have described no differences
n procedural failure between treatment strategies (6,7,21)
nd fewer access site–related complications (6,7,20,21),
ikely reflecting advances in operator experience, technique,
nd technology that also include vasodilator pharmacology
nd hydrophilic catheters. In our center, 353 UPLM per-
utaneous revascularization procedures were performed by
he TR approach (accounting for 43% of total UPLM cases)
n a setting of skilled operators using TR PCI in more than
0% of all PCI cases.
A radial artery approach for transcatheter coronary pro-
edures is supported by the consistency across comparative
rials demonstrating reductions in bleeding complications
nd need for blood product transfusion compared with
emoral access (4,5,7,18,19). In parallel with these studies
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1041omparing vascular access methods, TR PCI was associated
ith significantly fewer bleeding complications than were
irectionally consistent across standardized bleeding crite-
ia. Although not statistically significant between strategies,
emoral access complications (e.g., pseudoaneurysm, arte-
iovenous fistula) were numerically more common in the TF
ohort, with none observed in the TR cohort. Although this
nalysis may not directly correlate prolonged hospitalization
n the TF group with bleeding events or vascular access
omplications, the higher frequency of bleeding in the
bsence of other differential outcomes is suggestive. In
articular, differences in hospital stay were principally driven
y shorter post-procedural hospitalization for patients
reated with the TR method. Aside from potential direct
ost-savings related to avoidance of vascular and bleeding
omplications (23,24), a TR approach may also reduce
ospital expenses through decreased resource use and ab-
reviated length of hospitalization (3,9,25).
Both early and late clinical outcomes for each group in
his study were consistent with other large observational
nalyses of patients undergoing UPLM PCI (15). Favorable
utcomes may in part be attributed to technique (26,27),
ncluding high stent deployment pressure, kissing balloon
ost-dilation, and use of IVUS guidance (28), which are not
xcluded by a TR approach. Alternatively, despite differ-
nces in in-hospital bleeding events, late-term outcomes did
ot statistically differ according to vascular access method.
erhaps representing limitations in sample size and study
esign, this observation differs from larger comparative
tudies that have established the relationship between the
R PCI, reduced major bleeding and/or transfusion, and
ecreased early and late-term mortality (5,18).
tudy limitations. Despite propensity score adjustment,
omparisons from this analysis are limited by their retro-
pective and nonrandomized design in which operator bias
nd unmeasured confounders may preclude any definite
onclusion. Nevertheless, most clinically relevant patient
emographics did not statistically differ between TR and TF
roups, except for prevalence of distal bifurcation disease.
ven in this latter instance, TR patients were more com-
only treated with a single stent technique that may be
ssociated with a more favorable outcome compared with
-stent procedures (26,27). However, consistent with pre-
ious non–left main bifurcation strategy trials (29) and
ompared with prior comparative vascular access trials
eporting greater fluoroscopy time with radial artery cathe-
erization (6,22), a higher prevalence of single stent bifur-
ation procedures and overall lower incidence of bifurcation
isease may also in part explain lower fluoroscopy time and
ontrast volume use in the TR group. Similarly, although
tudy population size and operator selection of vascular
ccess may mitigate potential differences in low-frequency
ate clinical events between treatment groups, adverse event
ates were very similar, if not lower (bleeding, in particular)ith the TR method, representing a potential negative bias
gainst TR PCI. Further, radial artery access was not
dentified as a predictor of adverse outcome in multivariable
egression analysis. Finally, the observations of abbreviated
ospital duration and decreased procedural-related time and
rovisions with TR PCI must be cautiously interpreted
iven that these patients demonstrated somewhat lower
linical, angiographic, and procedural complexity factors—
ll of which may influence length of hospitalization and
esource use.
onclusions
ompared with a TF approach, TR percutaneous coronary
evascularization for UPLM disease is feasible and associ-
ted with similar procedural success, abbreviated hospital-
zation, reduced bleeding, and comparable late-term clinical
afety and efficacy. These results not only inform our
nderstanding of TR PCI regarding the procedural chal-
enges involved in the treatment of more complex and
igh-risk coronary anatomy, but also add to the evidence
asis associating TR PCI with reduced bleeding events and
esource use.
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